MCM
KNSA icon

MAI Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

MAI Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-185
Closed -$8.91K – 3481
2026
Q1 		$8.91K Buy
185
+180
+3,600% +$7.97K ﹤0.01% 3221
2025
Q4 		$207 Buy
+5
New +$201 ﹤0.01% 4036

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

MAI Capital Management's KNSA Position: Q2 2026 in Review

MAI Capital Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2026, closing a stake of 185 shares — an estimated $8.91K sold.

MAI Capital Management first reported a position in KNSA in Q4 2025 and held it in 2 quarters. The position peaked at $8.91K in Q1 2026. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • MAI Capital Management reported no remaining Kiniksa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 185 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $8.91K.
  • MAI Capital Management first reported a position in Kiniksa Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • MAI Capital Management's Kiniksa Pharmaceuticals position peaked at $8.91K in Q1 2026.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.